Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
244 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hodgkin Lymphoma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Hodgkin Lymphoma - Pipeline Review, H1 2015', provides an overview of the Hodgkin Lymphoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Hodgkin Lymphoma Overview 11 Therapeutics Development 12 Pipeline Products for Hodgkin Lymphoma - Overview 12 Pipeline Products for Hodgkin Lymphoma - Comparative Analysis 13 Hodgkin Lymphoma - Therapeutics under Development by Companies 14 Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 17 Hodgkin Lymphoma - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Hodgkin Lymphoma - Products under Development by Companies 21 Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 24 Hodgkin Lymphoma - Companies Involved in Therapeutics Development 25 4SC AG 25 Acetylon Pharmaceuticals, Inc. 26 Actinium Pharmaceuticals, Inc. 27 Affimed Therapeutics AG 28 Aptose Biosciences Inc. 29 AVEO Pharmaceuticals, Inc. 30 Bristol-Myers Squibb Company 31 Constellation Pharmaceuticals, Inc. 32 Dynavax Technologies Corporation 33 Gamida Cell Ltd. 34 Incyte Corporation 35 Johnson & Johnson 36 MABLife S.A.S 37 Merck & Co., Inc. 38 Novartis AG 39 Ono Pharmaceutical Co., Ltd. 40 Pharmacyclics, Inc. 41 Philogen S.p.A. 42 Seattle Genetics, Inc. 43 Sigma-Tau S.p.A. 44 Spectrum Pharmaceuticals, Inc. 45 Stemline Therapeutics, Inc. 46 Syndax Pharmaceuticals, Inc. 47 Takeda Oncology 48 Tekmira Pharmaceuticals Corp. 49 TG Therapeutics, Inc. 50 Hodgkin Lymphoma - Therapeutics Assessment 51 Assessment by Monotherapy Products 51 Assessment by Target 52 Assessment by Mechanism of Action 55 Assessment by Route of Administration 58 Assessment by Molecule Type 60 Drug Profiles 62 abexinostat hydrochloride - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 AFM-13 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 APTO-253 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 BMS-986016 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 brentuximab vedotin - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Cell Therapy 2 for Oncology and Infectious Disease - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Cell Therapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Cell Therapy to Target CD30 for Relapsed and Refractory Lymphomas - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Cell Therapy to Target LMP-1 and LMP-2 for Oncology - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Cell Therapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 CPI-0610 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Dendritic Cell Therapy for Oncology - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 entinostat - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Ferritarg - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 ficlatuzumab - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Iomab-B - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 ixazomib citrate - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 JNJ-40346527 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 LMP-400 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 LMP-776 - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 MDX-1401 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 MK-2206 - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 NiCord - Drug Profile 106 Product Description 106 Mechanism of Action 106 R&D Progress 106 nivolumab (recombinant) - Drug Profile 107 Product Description 107 Mechanism of Action 107 R&D Progress 107 NSC-678515 - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 panobinostat - Drug Profile 113 Product Description 113 Mechanism of Action 113 R&D Progress 113 pembrolizumab - Drug Profile 119 Product Description 119 Mechanism of Action 119 R&D Progress 119 pevonedistat hydrochloride - Drug Profile 123 Product Description 123 Mechanism of Action 123 R&D Progress 123 procarbazine hydrochloride - Drug Profile 125 Product Description 125 Mechanism of Action 125 R&D Progress 125 radretumab - Drug Profile 126 Product Description 126 Mechanism of Action 126 R&D Progress 126 resminostat - Drug Profile 128 Product Description 128 Mechanism of Action 128 R&D Progress 128 ricolinostat - Drug Profile 132 Product Description 132 Mechanism of Action 132 R&D Progress 132 RP-5264 - Drug Profile 134 Product Description 134 Mechanism of Action 134 R&D Progress 134 ruxolitinib phosphate - Drug Profile 136 Product Description 136 Mechanism of Action 136 R&D Progress 136 SD-101 - Drug Profile 141 Product Description 141 Mechanism of Action 141 R&D Progress 141 SL-101 - Drug Profile 143 Product Description 143 Mechanism of Action 143 R&D Progress 143 SL-501 - Drug Profile 144 Product Description 144 Mechanism of Action 144 R&D Progress 144 StemEx - Drug Profile 145 Product Description 145 Mechanism of Action 145 R&D Progress 145 TKM-PLK1 - Drug Profile 146 Product Description 146 Mechanism of Action 146 R&D Progress 146 vinorelbine tartrate liposomal - Drug Profile 148 Product Description 148 Mechanism of Action 148 R&D Progress 148 Hodgkin Lymphoma - Recent Pipeline Updates 150 Hodgkin Lymphoma - Dormant Projects 223 Hodgkin Lymphoma - Discontinued Products 226 Hodgkin Lymphoma - Product Development Milestones 227 Featured News & Press Releases 227 Dec 09, 2014: Affimed Presents Final Data for AFM13 Phase 1 Trial at ASH 227 Dec 08, 2014: Seattle Genetics Highlights Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations in Frontline and Salvage Hodgkin Lymphoma at ASH Annual Meeting 227 Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting 231 Dec 06, 2014: Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma 233 Dec 06, 2014: Data Investigating KEYTRUDA (pembrolizumab), Merck's Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting 235 Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014 236 Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting 238 Oct 13, 2014: Takeda's Adcetri (brentuximab vedotin) is the first ultra-orphan medicine to be accepted by the SMC via the new assessment process 239 Sep 29, 2014: Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS (Brentuximab Vedotin) for Consolidation in Post-Transplant Hodgkin Lymphoma 240 Sep 26, 2014: Seattle Genetics to Host Conference Call and Webcast on September 29, 2014 Regarding Top-line Data from ADCETRIS (brentuximab vedotin) Phase 3 AETHERA Clinical Trial 242 Appendix 243 Methodology 243 Coverage 243 Secondary Research 243 Primary Research 243 Expert Panel Validation 243 Contact Us 244 Disclaimer 244
List of Tables Number of Products under Development for Hodgkin Lymphoma, H1 2015 12 Number of Products under Development for Hodgkin Lymphoma - Comparative Analysis, H1 2015 13 Number of Products under Development by Companies, H1 2015 15 Number of Products under Development by Companies, H1 2015 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2015 17 Comparative Analysis by Late Stage Development, H1 2015 18 Comparative Analysis by Clinical Stage Development, H1 2015 19 Comparative Analysis by Early Stage Development, H1 2015 20 Products under Development by Companies, H1 2015 21 Products under Development by Companies, H1 2015 (Contd..1) 22 Products under Development by Companies, H1 2015 (Contd..2) 23 Products under Investigation by Universities/Institutes, H1 2015 24 Hodgkin Lymphoma - Pipeline by 4SC AG, H1 2015 25 Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 26 Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 27 Hodgkin Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2015 28 Hodgkin Lymphoma - Pipeline by Aptose Biosciences Inc., H1 2015 29 Hodgkin Lymphoma - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 30 Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2015 31 Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2015 32 Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H1 2015 33 Hodgkin Lymphoma - Pipeline by Gamida Cell Ltd., H1 2015 34 Hodgkin Lymphoma - Pipeline by Incyte Corporation, H1 2015 35 Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H1 2015 36 Hodgkin Lymphoma - Pipeline by MABLife S.A.S, H1 2015 37 Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H1 2015 38 Hodgkin Lymphoma - Pipeline by Novartis AG, H1 2015 39 Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 40 Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H1 2015 41 Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H1 2015 42 Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2015 43 Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H1 2015 44 Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 45 Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H1 2015 46 Hodgkin Lymphoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2015 47 Hodgkin Lymphoma - Pipeline by Takeda Oncology, H1 2015 48 Hodgkin Lymphoma - Pipeline by Tekmira Pharmaceuticals Corp., H1 2015 49 Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2015 50 Assessment by Monotherapy Products, H1 2015 51 Number of Products by Stage and Target, H1 2015 53 Number of Products by Stage and Mechanism of Action, H1 2015 56 Number of Products by Stage and Route of Administration, H1 2015 59 Number of Products by Stage and Molecule Type, H1 2015 61 Hodgkin Lymphoma Therapeutics - Recent Pipeline Updates, H1 2015 150 Hodgkin Lymphoma - Dormant Projects, H1 2015 223 Hodgkin Lymphoma - Dormant Projects (Contd..1), H1 2015 224 Hodgkin Lymphoma - Dormant Projects (Contd..2), H1 2015 225 Hodgkin Lymphoma - Discontinued Products, H1 2015 226
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
